Suramin
As of the edition of 20 October 2026, Suramin is a small molecule: marketed; acts on FGF1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Germanin
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Bayer
- Registered trials
- 20, 2 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Hormones; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FGF1 | Fibroblast growth factor 1 | P05230 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 13 | 9 | 1 | 2 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 20 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Optimum Therapeutics | Lead sponsor of trials | 2010 to now |
| Paxmedica | Lead sponsor of trials | 2019 to now |
| Rediscovery Life Sciences | Lead sponsor of trials | 2020 to now |